sickle cell disease

WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...

SUMMIT, N.J., August 25, 2026 Vascarta Inc. outlined new and previously generated preclinical and clinical evidence supporting the potential...

Austin, Texas, August 20, 2026 Raintree Systems has expanded its agentic artificial intelligence (AI) platform for rehabilitation therapy, introducing...

Summit, New Jersey, August 20, 2026 Vascarta Inc. has announced the initiation of a Phase I clinical study of...

BOSTON, July 1, 2026 Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the expanded...

NAIROBI, Kenya / KAMPALA, Uganda, June 19, 2026 African health leaders, government officials, clinicians, patient advocates, and international partners...

CAMBRIDGE, Mass., June 13, 2026 Agios Pharmaceuticals, Inc. announced detailed results from the 52-week double-blind portion of the global...

BOSTON, June 11, 2026 Vertex Pharmaceuticals announced new Phase 3 clinical data demonstrating the potential of CASGEVY® (exagamglogene autotemcel)...

CAMBRIDGE, Mass., June 1, 2026 Fulcrum Therapeutics announced the discontinuation of its lead investigational therapy pociredir for the treatment...

Bagsværd, Denmark, April 20, 2026 Novo Nordisk has announced breakthrough Phase 3 clinical trial results for etavopivat, a first-in-class...